Sotagliflozin reduces deaths, time spent in hospital for some patients with diabetes

Sotagliflozin increased the number of days alive and out of the hospital compared with placebo among patients with type 2 diabetes at high risk for intermittent hospitalization due to worsening heart failure, data show.